Dr. Kelley M Cornell, M.D., FACS Surgery Medicare: Accepting Medicare Assignments Practice Location: 200 Unicorn Park Dr Ste 302, Woburn, MA 01801 Phone: 781-756-2308 Fax: 781-756-4798 |
Nayomi K. Edirisinghe, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 7 Alfred Street, Suite #306, Woburn, MA 01801 Phone: 781-756-2308 Fax: 781-756-4798 |
News Archive
Trigemina, Inc., a Mountain View based privately-held biopharmaceutical company, reports positive results from a time-based interim analysis of its Phase IIa clinical trial in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston. The study compares intranasal oxytocin with placebo in patients suffering from CDH.
Tivantinib is an effective second-line therapy for hepatocellular carcinoma patients whose tumors exhibit high MET receptor tyrosine kinase expression, indicate phase II study results.
New California electronic medical billing regulations and revised paper medical billing requirements were released January 6th for public comment by California's Division of Workers Compensation (DWC). The regulations, part of the Division's 12-point plan to help control medical costs in California's workers' compensation system, will be signed into law in approximately 60 days.
Corventis, Inc., a developer of wireless cardiovascular solutions, announced today that it has received 510(k) clearance from the US Food and Drug Administration (FDA) to market its NUVANTâ„¢ Mobile Cardiac Telemetry (MCT) System for the detection of non-lethal arrhythmias. In addition, the company announced that its Monitoring Center has been approved by the Center for Medicare & Medicaid Services (CMS) as an Independent Diagnostic Testing Facility (IDTF). Corventis has also received approval to bill for services provided to patients with Medicare and several commercial insurers, paving the way for the NUVANT MCT System to be available across the United States.
Mylan Inc. today announced that it has entered into a settlement agreement with Shionogi Inc. and CIMA Labs Inc. that will resolve patent litigation related to Prednisolone Sodium Phosphate Orally Disintegrating Tablets (ODT), 10 mg, 15 mg and 30 mg.
› Verified 8 days ago